Navigation Links
Pixantrone Granted Fast Track Designation by FDA for Relapsed,Indolent NHL Patients

Proposed Phase III Trial Has the Potential to Demonstrate an Effect on a Serious or Life Threatening Aspect of This Disease

SEATTLE, May 07, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced today it received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed or refractory indolent non-Hodgkin's lymphoma (NHL). In granting fast track, the FDA noted that "relapsed or refractory indolent NHL is a serious and life threatening condition and is generally considered incurable. Results from a phase I and phase III study in patients with relapsed and/or refractory indolent non-Hodgkin's lymphoma suggest that pixantrone is active in this disease." The FDA also noted that the proposed phase III trial in combination with fludarabine and rituximab "has the potential to demonstrate an effect on a serious or life threatening aspect of this disease."

Prior results demonstrated that the addition of pixantrone to a fludarabine/rituximab-based regimen in relapsed or refractory indolent NHL yielded a 70 percent confirmed response/unconfirmed response (CR/uCR) rate. In that phase I/II study the estimated median duration of response was 25 months (range 2.3 to 43 months) and the estimated progression-free survival (PFS) rate at three years was 50.4 percent. A phase III trial of rituximab compared to rituximab plus pixantrone in relapsed or refractory indolent NHL had a 61 percent overall improvement in time to tumor progression (TTP) compared to rituximab alone (395 days vs. 245 days). In that randomized trial, the median TTP estimate for pixantrone/rituximab was 13.2 months compared to 8.1 months for rituximab alone (hazard ratio 0.13, log rank p< 0.001). The overall response rate in the pixantrone/rituximab arm was 75 percent versus 33 percent in the rituximab arm with a CR rate of 30 percent in the pixantrone/rituximab arm versus 11 p ercent in the rituximab arm.

"With fast track designation already granted for pixantrone in aggressive NHL, this designation for indolent NHL is an important step in the development of this product and may help us bring this potentially life-saving drug to patients more quickly," stated James A. Bianco, M.D., President and CEO of CTI.

CTI is awaiting feedback from the FDA on the design of its PIX303 trial, which will examine the time to disease progression for the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of fludarabine and rituximab (F-R) in the treatment of patients who have failed up to five prior treatments for relapsed or refractory NHL. The trial, submitted under the FDA's Special Protocol Assessment procedure, is expected to enroll 300 patients beginning in the second quarter with interim data by mid-2008

Pixantrone Clinical Trials

Pixantrone has been studied extensively in aggressive NHL patients, including two ongoing studies, a phase III single agent trial, known as EXTEND and a phase II combination study, known as RAPID. The EXTEND trial explores the role of single agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens. Patients are randomized to receive either pixantrone or another single-agent drug of physician's choice currently used for the treatment of this patient population. An interim look is planned for the summer of 2007.

The RAPID trial is a first-line phase II study in aggressive NHL patients that will evaluate pixantrone as part of the CPOP-R combination regimen (cyclophosphpamide, pixantrone, vincristine, prednisone and rituximab) compared to the standard treatment regimen, CHOP-R (cyclophosphpamide, doxorubicin, vincristine, prednisone and rituximab). This study will explore the potential cardiac safety benefits of pixantrone in chemotherapy naïve patients when compared directly to doxorubicin.

Fast Track Designation

Fast track designation means the FDA will facilitate and expedite the development and review of the application for the approval of a new drug if it is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to address an unmet medical need. An expedited review as defined by the FDA user fee performance goals provides for a review within six months.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com .

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with p ixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:

    Cell Therapeutics, Inc.

    Dan Eramian

    T: 206.272.4343

    C: 206.854.1200

    Susan Callahan

    T: 206.272.4472

    F: 206.272.4434

    E: 

    www.cticseattle.com/media.htm


    Investors Contact:

    Cell Therapeutics, Inc.

    Leah Grant

    T: 206.282.7100

    F: 206.272.4434

    E: 

    www.cticseattle.com/investors.htm

media@ctiseattle.com invest@ctiseattle.com

CONTACT: media, Dan Eramian, +1-206-272-4343, mobile, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, fax, +1-206-272-4434,, or investors, Leah Grant, +1-206-282-7100, fax,+1-206-272-4434, , all of Cell Therapeutics, Inc. media@ctiseattle.com invest@ctiseattle.com

Web site: http://www.cticseattle.com//< /p>

Ticker Symbol: (NASDAQ-NMS:CTIC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... New York , February 10, 2016 ... Growth, Trends and Forecast 2015 - 2023 ", reveals that ... rather slow growth from 2015 to 2023 owing to patent ... a meager CAGR of 1.30% during the forecast period, the ... to US$38.9 bn in 2023. --> Antibacterial Drugs ...
(Date:2/10/2016)... 10, 2016 Intouch Solutions, a leading marketing ... industry-wide trend regarding the evolution of digital sales ... efficiently deliver compelling sales presentations via tablets. After ... in 2015, Intouch uncovered that while most pharmaceutical ... DSAs, many are not using them effectively during ...
(Date:2/10/2016)... , Feb. 9, 2016 ... Drug Administration (FDA) met with its Arthritis ... proposed biosimilar of Johnson & Johnson,s Remicade ... be approved in the U.S. The Biologics ... physician groups - Alliance for Patient Access, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):